Efficacy of Combined Gemcitabine/Cisplatin Chemotherapy for Locally Advanced or Metastatic Urothelial Cancer
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: We wanted to determine and report on the outcome of combined gemcitabine/cisplatin chemotherapy for patients suffering with locally advanced or metastatic urothelial cancer. Materials and Methods: Between July 1999 and December 2004, 43 selected patients were enrolled in this study. Group 1 (the adjuvant chemotherapy group) had undergone radical surgery with removal of evident tumor from the following primary sites: bladder (n=8), renal pelvis (n=7) and ureter (n=3). Group 2 (the salvage chemotherapy group) had undergone palliative surgery with a remnant tumor at the following primary sites; bladder (n=23) and renal pelvis (n=2). All the patients were given gemcitabine/ciplatin and they evaluated for the therapeutic effect and toxicity. The patients were initially treated with gemcitabine 1000 mg/m2 intravenously for 30 minutes on days 1, 8 and 15 of a 28-day cycle, and cisplatin 70 mg/m2 was administered intravenously on day 1 using prehydration measures. Results: Group 1: The median follow-up period was 16.5 months. The mean age was 63 years (males: 15 cases, females: 3 cases), and eleven patients (61%) remained alive. The estimated median relapse-free survival period and 2-year survival rate were 24 months and 63%, respectively. Group 2: the median follow-up period was 20 months, the mean patient age was 63.8 years (males: 22 cases, females: 3 cases), and nine patients (36%) remained alive. The overall response and 2-year survival rates were 36% and 43%, respectively. Toxicities: Grade 3 toxicities developed in 14 cycles during the total 232 cycles. Grade 4 toxicity did not occur. Conclusions: The results of this study confirm that adjuvant and salvage chemotherapy with using gemcitabine and cisplatin is tolerable and safe. (Cancer Res Treat. 2006;38:78-84)
Abstract
Purpose: We wanted to determine and report on the outcome of combined gemcitabine/cisplatin chemotherapy for patients suffering with locally advanced or metastatic urothelial cancer. Materials and Methods: Between July 1999 and December 2004, 43 selected patients were enrolled in this study. Group 1 (the adjuvant chemotherapy group) had undergone radical surgery with removal of evident tumor from the following primary sites: bladder (n=8), renal pelvis (n=7) and ureter (n=3). Group 2 (the salvage chemotherapy group) had undergone palliative surgery with a remnant tumor at the following primary sites; bladder (n=23) and renal pelvis (n=2). All the patients were given gemcitabine/ciplatin and they evaluated for the therapeutic effect and toxicity. The patients were initially treated with gemcitabine 1000 mg/m2 intravenously for 30 minutes on days 1, 8 and 15 of a 28-day cycle, and cisplatin 70 mg/m2 was administered intravenously on day 1 using prehydration measures. Results: Group 1: The median follow-up period was 16.5 months. The mean age was 63 years (males: 15 cases, females: 3 cases), and eleven patients (61%) remained alive. The estimated median relapse-free survival period and 2-year survival rate were 24 months and 63%, respectively. Group 2: the median follow-up period was 20 months, the mean patient age was 63.8 years (males: 22 cases, females: 3 cases), and nine patients (36%) remained alive. The overall response and 2-year survival rates were 36% and 43%, respectively. Toxicities: Grade 3 toxicities developed in 14 cycles during the total 232 cycles. Grade 4 toxicity did not occur. Conclusions: The results of this study confirm that adjuvant and salvage chemotherapy with using gemcitabine and cisplatin is tolerable and safe. (Cancer Res Treat. 2006;38:78-84)
참고문헌 (23)
- "Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer", 18, pp.3068~3077 (2000)
- "Preliminary results of M-VAC for transitional cell carcinoma of the urothelium", pp.403~7 (1985)
- "Nonbladder primary site of transitional cell carcinoma (TCC) does not affect probability of response to M-VAC or survival", 17(337a) (1998)
- "M-VAC for advanced transitional cell carcinoma of the urothelium and patterns of response and relapse", pp.2448~58 (1989)
- "chemotherapy for transitional cell carcinoma", pp.2 289~92 (1989), the Princess Margaret Hospital experience
- "Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma", 15, pp.2564~2569 (1997)
- "A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma", 98, pp.1863~1869 (2003)
- "New drugs and new approaches for the treatment of metastatic urothelial cancer", 20, pp.158~166 (2002)
- "New chemotherapy combinations for advanced bladder cancer", 11, pp.517~522 (2001)
- "Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: a phase II multicenter trial", 164, pp.53~56 (2000)
- "Chemotherapy", pp.492~3 (2004), Churchill Livingstone
- "Phase II study of gemcitabine plus cisplatin in patients with metastatic breast cancer", 28, pp.195~200 (2005)
- "Concurrent chemoradiotherapy with gemcitabine and cisplatin after incomplete (R1) resection of locally advanced pancreatic carcinoma", 58, pp.768~772 (2004)
- "Cisplatin and gemcitabine induction chemotherapy followed by concurrent chemoradiotherapy or surgery for locally advanced non-small cell lung cancer", 35, pp.336~342 (2005)
- "Cancer Care Ontario Practice Guidelines Initiative Genitourinary Cancer Disease Site Group", 9, pp.1625~1633 (2002)
- "The role of systemic chemotherapy in the management of muscle-invasive bladder cancer", 3, pp.738~747 (2002)
- "Impact of adjuvant systemic chemotherapy on postoperative survival in patients with high-risk urothelial cancer", 11, pp.456~460 (2004)
- "Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer", 18, pp.3068~3077 (2000)
- "Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer", 18, pp.1921~1927 (2000)
- "Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer", 17, pp.2876~2881 (1999)
- "Gemcitabine", cisplatin vs MVAC 5 year survival outcome of the phase III study of chemotherapy of advanced urothelial carcinoma in Germany, 2003, pp.42, 1074~1086
- "Overview of gemcitabine triplets in metastatic bladder cancer", 45, pp.191~197 (2003)
- "Gemcitabine plus cisplatin in adjuvant regimen for bladder cancer", 71, pp.37~40 (2003)